AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Tarsus Pharmaceuticals In... (TARS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

48.89

-0.66 (-1.33%)

At close: Feb 20, 2025, 3:59 PM

48.72

-0.35%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	46.25
Market Cap	1.87B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.75
PE Ratio (ttm)	-13.04
Forward PE	n/a
Analyst	Buy

Ask	51.14
Volume	224,654
Avg. Volume (20D)	569,825
Open	49.38
Previous Close	49.55
Day's Range	48.50 - 49.52
52-Week Range	20.08 - 57.28
Beta	undefined

About TARS

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; a...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 16, 2020

Employees 244

Stock Exchange NASDAQ

Ticker Symbol TARS

Website https://www.tarsusrx.com

Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for TARS stock is "Buy." The 12-month stock price forecast is $61, which is an increase of 24.77% from the latest price.

Buy 83.33%

Hold 16.67%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Tarsus Pharmaceuticals Inc. is scheduled to release its earnings on Mar 4, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

+0.3%

Tarsus Pharmaceuticals shares are trading higher a... Unlock content with Pro Subscription

3 months ago

-2.23%

Tarsus Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.

News

1 month ago · zacks.com

Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Tarsus Pharmaceuticals (TARS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Str...

1 month ago · zacks.com

4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow

Here, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025.

2 months ago · seekingalpha.com

Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks

Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics.

2 months ago · zacks.com

Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet

The consensus price target hints at a 27% upside potential for Tarsus Pharmaceuticals (TARS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni...